


May 18-19, 2016; Amsterdam; the Netherlands

# 6<sup>TH</sup> DUTCH BREAST PATHOLOGY COURSE

*'Finding the balance between overtreatment and undertreatment'*



Welcome on behalf of

- Koen van de Vijver
- Hugo Horlings
- Mathilde Almekinders
- Emilie Groen
- José van den Berg
- Sanneke Heijker




## Pathology is about

- Who to treat? Prognostic factors
- How to treat? Predictive factors
  
- Adequate classification
- Driving initial and subsequent treatment

Different disciplines → Different answers

- Radiologists → *Correlation*
- Surgeons → *Watchful waiting or surgery*
- Medical oncologists → *Metastases / dead of disease*
- Radiation oncologists → *Risk on local recurrence*

## Why do many patients not benefit?



90% of the patients with ER-positive breast cancer receive endocrine treatment without any benefit!

EBCTCG, *Lancet* (2011) 378:771



## Design of an animal experiment

- Criteria: the three Rs
  - Replacement
  - Reduction
  - Refinement
- Experiment proposed
  - Expected effect: 5% absolute survival gain (NMNT-20)
  - Sufficient statistical power if n=100
  - Approval by the Animal Ethical Committee ....

**REJECTED**



## Systemic treatment is not very precise

- Absolute overall survival benefit of systemic treatment is limited
  - For chemotherapy is 5-20% at follow-up of 10 years
  - For endocrine treatment ca. 10-20% at follow-up of 15 years
- Many women receive systemic treatment without benefit
  - Up to 95% for chemotherapy
  - Up to 90% for endocrine treatment
- Disclaimer
  - These are general numbers, so percentages for subgroups may differ

EBCTCG, *Lancet* (2011), 378: 771-74; EBCTCG, *Lancet* (2012), 379: 432-444




## There is often over-treatment of DCIS

- Minority will progress into IBC
- But which one will and which one will not?



## More than meets the eye



Hanahan and Weinberg, *Cell* (2011) 144:646



### PROGRAM

Wednesday May 18, 2016

**8.30-9.00**

Registration & Coffee

**09.00-09.10**

Introduction  
Jelle Wesseling, pathologist  
The Netherlands Cancer Institute

**09.10-09.40**

The role of pathology in minimizing harm by breast surgery  
Hester Oldenburg, surgical oncologist  
The Netherlands Cancer Institute

**09.40-10.45**

Conquering overdiagnosis by cytopathology  
Claudette Loo, radiologist  
The Netherlands Cancer Institute & Koen van de Vijver, pathologist  
The Netherlands Cancer Institute

**10.45-11.00**

Coffee break

**11.00-12.00**

Workshop: do neuroendocrine features of breast lesions really matter?  
Malcolm Hayes, pathologist,  
University of British Columbia, Vancouver

**12.00-13.00**

The multidisciplinary clinical breast care team meeting at the NKI-AVL  
Breast team The Netherlands Cancer Institute

**13.00-13.45**

Lunch

**13.45-14.30**

Distinguishing harmless from hazardous breast lesions  
Jelle Wesseling, pathologist  
The Netherlands Cancer Institute

**14.30-15.30**

Diagnosis, treatment and prognosis of adenomyoepithelial lesions  
Malcolm Hayes, pathologist  
University of British Columbia, Vancouver

**15.30-15.45**

Tea Break

**15.45-16.15**

The role of pathology in saving the axilla  
Mila Donker, radiation oncologist in training  
The Netherlands Cancer Institute

**16.15-16.45**

Improving response prediction by pathology in neoadjuvant treatment  
Esther Lips, molecular biologist  
The Netherlands Cancer Institute

**16.45-17.30**

Debate: Standard breast pathology: too little and too much  
Pro too little and too much: Emiel Rutgers, breast surgeon  
The Netherlands Cancer Institute  
Pro standard: TBA

**18.30-22.30**

Drinks and dinner  
Location to be announced



## PROGRAM

Thursday May 19, 2016

### 09.00-10.15

Workshop: diagnosis and prognosis of papillary lesions  
Malcolm Hayes, pathologist  
University of British Columbia, Vancouver

### 10.15-10.30

Coffee Break

### 10.30-11.15

The role of pathology in targeting neoadjuvant treatment  
Gabe Sonke, medical oncologist  
The Netherlands Cancer Institute

### 11.15-12.30

Workshop breast lesions illustrating the overdiagnosis dilemma  
All participants are invited to submit a case illustrating the theme of this course. Maximal 15 cases will be selected for a plenary discussion. See instructions above. This invitation will be sent after your registration has been confirmed.

### 12.30-13.30

Lunch

### 13.30-14.00

Molecular pathology in precise breast cancer management  
Hugo Horlings, pathologist  
The Netherlands Cancer Institute

### 14.00-14.45

Striving for the optimum in breast conserving therapy  
Harry Bartelink, radiation oncologist  
The Netherlands Cancer Institute

### 14.45-15.45

The role of the pathologist in de-escalating systemic treatment  
Carolien Schröder, medical oncologist,  
University Medical Center Groningen, NL

### 15.45-16.00

Tea Break

### 16.00-16.30

Debate: Histopathology vs. molecular tests driving systemic treatment decisions  
Pro histopathology: Carolien Schröder, medical oncologist  
University Medical Center Groningen, NL  
Pro molecular tests: Sabine Linn, medical oncologist  
The Netherlands Cancer Institute

### 16.30-17.00

Evaluation and closing remarks